Pharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Analytical Operations, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Pharm Res. 2021 Mar;38(3):531-548. doi: 10.1007/s11095-021-03021-z. Epub 2021 Mar 12.
Enzymatic polysorbate (PS) degradation and resulting free fatty acid (FFA) particles are detrimental to biopharmaceutical drug product (DP) stability. Different types and grades of polysorbate have varying propensity to form FFA particles. This work evaluates the homogenous all-oleate (AO) PS80 alongside heterogeneous PS20 and PS80 grades in terms its propensity to form FFA particles and other important attributes like interfacial protection and oxidation susceptibility.
FFA particle formation rates were compared by degrading PS using non-immobilized hydrolases and fast degrading DP formulations. Interfacial protection of monoclonal antibodies (mAbs) was assessed by agitation studies in saline using non-degraded and degraded PS. Several antioxidants were assessed for their ability to mitigate AO PS80 oxidation and subsequent mAb oxidation by a 40°C placebo stability study and a 2, 2'-Azobis (2-amidinopropane) dihydrochloride stress model, respectively.
Visible and subvisible particles were significantly delayed in AO PS80 formulations compared with heterogeneous PS20 and PS80 formulations. Non-degraded AO PS80 was less protective of mAbs against the air-water interface compared with heterogeneous PS20. Interfacial protection by AO PS80 improved upon degradation owing to high surface activity of FFAs. Diethylenetriaminepentaacetic acid (DTPA) completely mitigated AO PS80 oxidation unlike L-methionine and N-Acetyl-DL-Tryptophan. However, DTPA did not mitigate radical mediated mAb oxidation.
AO PS80 is a promising alternative to reduce FFA particle formation compared with other PS types and grades. However, limitations observed here---such as lower protection against interfacial stresses and higher propensity for oxidation---need to be considered in assessing the risk/benefit ratio in using AO PS80.
酶促聚山梨酯(PS)降解和由此产生的游离脂肪酸(FFA)颗粒对生物制药产品(DP)的稳定性有害。不同类型和级别的聚山梨酯形成 FFA 颗粒的倾向不同。本工作评估了均相全油酸(AO)PS80 以及多相 PS20 和 PS80 级别的 PS 在形成 FFA 颗粒方面的倾向,以及界面保护和氧化易感性等其他重要特性。
通过使用非固定化水解酶和快速降解 DP 制剂来比较 PS 的 FFA 颗粒形成速率。通过在盐水中进行搅拌研究来评估单克隆抗体(mAb)的界面保护作用,使用非降解和降解的 PS。分别通过 40°C 安慰剂稳定性研究和 2,2'-偶氮双(2-脒基丙烷)二盐酸盐应激模型评估几种抗氧化剂缓解 AO PS80 氧化和随后 mAb 氧化的能力。
与多相 PS20 和 PS80 制剂相比,AO PS80 制剂中可见和亚可见颗粒明显延迟。与多相 PS20 相比,非降解的 AO PS80 对 mAb 对抗空气-水界面的保护作用较小。由于 FFAs 的高表面活性,AO PS80 降解后的界面保护作用得到改善。乙二胺四乙酸(DTPA)完全缓解了 AO PS80 的氧化,而 L-蛋氨酸和 N-乙酰-DL-色氨酸则不然。然而,DTPA 并不能缓解自由基介导的 mAb 氧化。
与其他 PS 类型和级别相比,AO PS80 是一种有前途的替代物,可以减少 FFA 颗粒的形成。然而,这里观察到的限制,如对界面应力的保护较低和氧化倾向较高,在评估使用 AO PS80 的风险/收益比时需要考虑。